Tempus AI, Inc. (TEM)
| Market Cap | 13.82B -7.4% |
| Revenue (ttm) | 1.43B +50.4% |
| Net Income | -254.43M |
| EPS | -1.43 |
| Shares Out | 180.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,375,411 |
| Open | 76.47 |
| Previous Close | 77.19 |
| Day's Range | 75.88 - 78.97 |
| 52-Week Range | 40.77 - 104.32 |
| Beta | 3.72 |
| Analysts | Buy |
| Price Target | 68.56 (-10.48%) |
| Est. Earnings | Nov 3, 2026 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $68.56, which is a decrease of -10.48% from the latest price.
News
Tempus AI, Recursion extend data license agreement, enter new license agreement
Tempus AI (TEM) announced an extension of its data license agreement with Recursion Pharmaceuticals (RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will li...
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies ...
Tempus AI initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Tempus AI (TEM) with a Neutral rating and $75 price target The company offers “highly visible” near-term growth in its diagnostics business but faces mid-term…
Tempus AI stock is soaring: does it have more upside to go?
Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization ab...
Tempus AI Stock (TEM) Surges 40% in a Week — Is More Upside Ahead?
Shares of Tempus AI ($TEM) jumped 15% Thursday, extending their five-day gain to nearly 40%. The rally came after CEO Eric Lefkofsky outlined the company’s growth plans at the Morgan…
Tempus AI Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong demand in diagnostics and data licensing, FDA approvals, and strategic acquisitions are driving robust growth and margin expansion. AI adoption and partnerships position the company for continued leadership in oncology and data-driven healthcare, with significant upside from latent demand and new markets.
Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI
Eric Lefkofsky, Tempus AI founder and CEO, joins 'The Exchange' to discuss AI's role in healthcare, advancing cancer research with AI, personalized vaccines, and more.
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.'
Tempus AI to build multimodal whole-genome dataset for AI-driven healthcare
Tempus AI (TEM) announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create th...
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the...
Tempus AI price target raised to $66 from $56 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI (TEM) to $66 from $56 and keeps a Buy rating on the shares. The firm says Merck’s…
Tempus AI awarded up to $9.5M from ARPA-H for autonomous AI in cardiology
Tempus AI (TEM) announced that it has been selected by the Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, to receive…
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of ...
Tempus AI initiated with a Neutral at UBS
UBS analyst Douglas Schenkel initiated coverage of Tempus AI (TEM) with a Neutral rating and $70 price target The firm initiated and resumed 25 life science and diagnostics tools companies.
Tempus AI initiated with a Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Jamie Clark initiated coverage of Tempus AI (TEM) with a Neutral rating and $67 price target The company offers xT-CDx, a tumor-informed treatment selection test…
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conf...
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Cantor Fitzgerald bullish on Tempus AI, initiates with an Overweight
As previously reported, Cantor Fitzgerald analyst Sarah James initiated coverage of Tempus AI (TEM) with an Overweight rating and $80 price target implying 28% upside in the firm’s Base Case…
Tempus AI initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Tempus AI (TEM) with an Overweight rating and $80 price target
Top Performing Leveraged/Inverse ETFs: 08/23/2026
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an...
Tempus AI stock is soaring and it has Moderna to thank
Tempus AI (TEM) stock ripped higher on August 19 as third-party clinical breakthroughs triggered a technical short squeeze. As investors cheered TEM, it broke decisively above its major moving average...
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO l...
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating tha...